

OncoPharm
John Bossaer
OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.
Episodes
Mentioned books

Aug 7, 2025 • 12min
Dordaviprone & RCT to prevent ADRs
This week's episode discusses the first-in-class agent, dordaviprone and a randomized control trial that demonstrated an oncology pharmacists led to decreased rates of adverse drug reactions (ADRs) in a Hem/Onc clinic.
Dordaviprone data: https://doi.org/10.1200/jco.23.01134
Alabassi AK, et al. Role of a designated pharmacist in reducing adverse drug reaction rates and preventing potential medication errors in hematology-oncology: a randomized controlled trial. JCO Oncology Practice: https://doi.org/10.1200/OP-25-00158

Jul 31, 2025 • 10min
ProMACE-CytaBOM
More isn't always better. Our Landkmarks of OncoPharm series covers lessons learned from the ProMACE-CytaBOM regimen for NHL.
ProMACE-CytaBOM: https://www.annalsofoncology.org/article/S0923-7534(20)31592-1/pdf
RCT vs. CHOP (& others): https://www.nejm.org/doi/full/10.1056/NEJM199304083281404

Jul 17, 2025 • 11min
Testicular Cancer in a Nutshell
A brief overview of testicular cancer

Jul 10, 2025 • 11min
Supportive Care Updates
A few supportive care updates:
1. Skin prophylaxis to prevent severe dermatologic toxicity with Nivo/Ipi.
Note* published in JCO Oncology Practice (NOT JAMA Oncol as stated in the episode
Link: https://doi.org/10.1200/OP-25-00100
2. Stampede-Metformin and how metformin has some beneficial effects in prostate cancer patients who don't have diabetes
Link: https://doi.org/10.1016/S1470-2045(25)00231-1

Jul 3, 2025 • 10min
Linvoseltamab & sunvozertinib
Two new drug approvals to talk about (after I misplaced my notes!)

Jun 25, 2025 • 10min
Antiandrogen Withdrawal
Antiandrogen withdrawal is an historically well described phenomenon where prostate cancer patients experience PSA responses AFTER stopping their anti-androgen. But does this happen with today's 2nd generation antiandrogens?

Jun 19, 2025 • 28min
June 2025 Updates
A plethora of recent updates:
-Pembrolizumab (perioperative) in head & neck cancer (Keynote-689)
-Prostate cancer updates on cabozantinib/atezolizumab (yes, really) and talazoparib
-Pirtobrutinib improves PFS in CLL
-Zanubrutinib has a new dosage form on the way
-Another mitomycin product approved with "reverse thermal properties"
-A new regimen for FL of tafasitamab/rituximab/lenalidomide
-A comparison of the new ROS1-inhibitor, taltrectenib, compared to other 1st-line treatment options

Jun 5, 2025 • 14min
ASCO 2025
A recap of notable updates from ASCO 2025
1. Destiny-Breast09
2. BREAKWATER
3. ATOMIC
4. Delphi-304
5. CM 816 OS update
6. C-POST
7. Matterhorn

May 29, 2025 • 11min
CLEOPATRA
Our Landmarks of OncoPharm series returns to discuss the CLEOPATRA study, which established docetaxel, trastuzumab, pertuzumab (THP) as a standard first-line regimen for metastatic HER2-amplified breast cancer.

May 22, 2025 • 15min
Talking about cancer misinformation
If you've been struggling with how to talk to patients about ivermectin for cancer, then this podcast is for you.
1. Cancer misinformation on social media (Loeb, et al): https://doi.org/10.3322/caac.21857
2. Clinician communication with patients about cancer misinformation (Bylund, et al): https://doi.org/10.1200/OP.22.00526